Literature DB >> 21682959

A neglected research approach to prevent acquired drug resistance when treating new tuberculosis patients.

T Moulding1.   

Abstract

The occurrence of significant drug resistance in many countries, coupled with known problems in delivering directly observed therapy (DOT), calls for a re-examination of tuberculosis (TB) treatment delivery strategies. Electronic medication monitors, devices that determine when medication is removed from containers, and videophone-based strategies are being introduced to determine if they can effectively differentiate 1) patients who are adequately adherent to self-administered treatment (SAT), 2) less reliable patients who could be successfully treated with SAT if given more intensive counseling and 3) patients who require DOT. The adherence record could be used in deciding on compensatory longer treatment when poor adherence occurs. The time saved not giving DOT to all patients could be used to retrieve defaulters. Together these components constitute a monitor-based strategy. The program could be extended to supervise the adherence of private patients to medication provided by trained and subsidized pharmacies with the physicians or, when necessary, health departments managing poorly adherent patients. When patients move, the device could transfer essential data to the new care giver. To obtain optimal results, the requirements for the best possible devices and procedures for dealing with poor adherence need to be carefully evaluated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21682959     DOI: 10.5588/ijtld.10.0486

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  3 in total

1.  mHealth for Tuberculosis Treatment Adherence: A Framework to Guide Ethical Planning, Implementation, and Evaluation.

Authors:  Michael J DiStefano; Harald Schmidt
Journal:  Glob Health Sci Pract       Date:  2016-06-27

2.  Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China.

Authors:  Ni Wang; Hui Zhang; Yang Zhou; Hui Jiang; Bing Dai; Miaomiao Sun; Ying Li; Amelia Kinter; Fei Huang
Journal:  BMC Infect Dis       Date:  2019-10-15       Impact factor: 3.090

3.  A randomised controlled trial to evaluate a medication monitoring system for TB treatment.

Authors:  J Acosta; P Flores; M Alarcón; M Grande-Ortiz; L Moreno-Exebio; Z M Puyen
Journal:  Int J Tuberc Lung Dis       Date:  2022-01-01       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.